
RNA • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold RNA in your mock portfolio yet.
Avidity Biosciences is currently unprofitable, as reflected in its negative EPS and PE ratio. The figures are consistent with an early‑stage or clinical‑stage biotech that is investing heavily in R&D without commercialized products. From the limited data provided, the financial profile leans clearly loss‑making, which is a headwind from a pure fundamentals standpoint.
The stock trades at $72.43, modestly up 0.8% over the last month but far above its 200‑day moving average of $45.84, indicating a sharp prior run‑up. An RSI of 83.62 signals overbought conditions and elevated risk of a pullback. Price momentum has been strong historically, but current technicals suggest stretched valuation in the near term.
Alternative data for Avidity Biosciences is mixed and relatively muted. Web traffic is modest, job postings are flat at zero, and social media presence is small but slightly growing on LinkedIn while shrinking on Twitter/X. Overall, these signals do not currently point to a strong inflection in investor, customer, or hiring activity.
Avidity Biosciences shows a classic high‑risk biotech profile: unprofitable fundamentals, a strongly appreciated share price, and currently overbought technicals. Alternative data signals are modest and do not strongly confirm either a major positive or negative inflection. Overall, the setup appears balanced between upside optionality on future developments and near‑term downside risk from stretched technicals and lack of earnings support.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: